Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial
The latest analysis confirms that first-day accuracy - a critical performance metric for CGM users - shows an approximately 35% improvement in Mean Absolute Relative Difference (MARD) and a more than ...
Trinity Biotech (NASDAQ:TRIB) Earns Hold Rating from Analysts at StockNews.com
StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB – Free Report) in a research note released on Friday morning. The firm issued a hold rating on the stock. Trinity Biotech Price ...
Business Insider26d
Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology
DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions ...
Yahoo Finance3d
Trinity Biotech plc (TRIB)
Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc ...
TipRanks on MSN17d
Trinity Biotech’s CGM System Shows Breakthrough Improvements
Trinity Biotech ( ($TRIB) ) has shared an update. On February 6, 2025, Trinity Biotech announced significant improvements in its continuous ...
Nasdaq26d
Trinity Biotech Announces Promising Pre-Pivotal Trial Results for Next-Generation Continuous Glucose Monitoring System
Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management.
Investing19d
Trinity Biotech secures US funding for HIV tests
DUBLIN, Ireland - Trinity Biotech plc (NASDAQ:TRIB), a leading provider of diagnostic solutions for the healthcare industry, today announced the continuation of U.S. government funding for its HIV ...